Dr. Powles on Monitoring Immunotherapy Effects in Patients with RCC

Thomas Powles, MD, MBBS, MRCP
Published: Friday, Jul 12, 2019



Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses the importance of accurately assessing the toxicity profiles of immunotherapies for renal cell carcinoma (RCC).

Powles believes immunotherapies are going to change practice; therefore, physicians need to learn how to optimally administer them. Overall, the toxicity profile for immunotherapy is acceptable, but it is important to pay close attention to adverse events, such as diarrhea and transaminitis, which were historically treated with VEGF-targeted therapy or stopping treatment. Physicians can intervene with steroids where appropriate. Powles recommends physicians go through a period of education and training to become well-informed on immune-related toxicities, which seems prominent when given in combination with VEGF targeted therapy.

Powles has treated several patients with axitinib (Inlyta) and pembrolizumab (Keytruda) and the majority do very well with a combination. However, when the combination was first being tested, Powles needed to make sure the dosing was optimized, patients were educated properly, and if problems occurred, patients knew who to contact. Closely monitoring the effects of immunotherapy in RCC is going to be really important for the future, according to Powles.
SELECTED
LANGUAGE


Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses the importance of accurately assessing the toxicity profiles of immunotherapies for renal cell carcinoma (RCC).

Powles believes immunotherapies are going to change practice; therefore, physicians need to learn how to optimally administer them. Overall, the toxicity profile for immunotherapy is acceptable, but it is important to pay close attention to adverse events, such as diarrhea and transaminitis, which were historically treated with VEGF-targeted therapy or stopping treatment. Physicians can intervene with steroids where appropriate. Powles recommends physicians go through a period of education and training to become well-informed on immune-related toxicities, which seems prominent when given in combination with VEGF targeted therapy.

Powles has treated several patients with axitinib (Inlyta) and pembrolizumab (Keytruda) and the majority do very well with a combination. However, when the combination was first being tested, Powles needed to make sure the dosing was optimized, patients were educated properly, and if problems occurred, patients knew who to contact. Closely monitoring the effects of immunotherapy in RCC is going to be really important for the future, according to Powles.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x